Treatment of type 2 diabetes

被引:5
|
作者
Meier, J. J. [1 ]
机构
[1] Klinikum Ruhr Univ Bochum, Univ Klinikum St Josef Hosp, Abt Diabetol, Gudrunstr 56, D-44791 Bochum, Germany
来源
INTERNIST | 2016年 / 57卷 / 02期
关键词
Metformin; Sulfonylurea compounds; Glucagon-like peptide 1 analogues; Dipeptidyl-peptidase; 4; inhibitors; Sodium-glucose transporter 2 inhibitors; JEJUNAL BYPASS LINER; CARDIOVASCULAR OUTCOMES; BARIATRIC SURGERY; GLYCEMIC CONTROL; METFORMIN; THERAPY; RISK; DAPAGLIFLOZIN; ASSOCIATION; MELLITUS;
D O I
10.1007/s00108-015-0002-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New glucose-lowering drugs have raised the complexity of diabetes treatment in recent years. While metformin is still the first choice in monotherapy for most cases, various options exist for dual combination therapy. In addition, combinations of three different oral glucose-lowering drugs are increasingly used. Insulin therapy is typically initiated using once daily administration of a long-acting insulin. If basal insulin alone is no longer sufficient, treatment can be intensified by adding short-acting insulin at mealtime or by combining basal insulin with oral glucose-lowering drugs or a glucagon-like peptide (GLP)-1 analogue. The choice of the most appropriate glucose-lowering drug should take into account not only the glucose-lowering efficacy, but also the side effect profile of the respective agents; economic factors must be considered as well. Modern treatment of type 2 diabetes should aim for near-normal glucose control.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 50 条
  • [1] Treatment of type 2 diabetes
    Landgraf, Ruediger
    Aberle, Jens
    Birkenfeld, Andreas L.
    Gallwitz, Baptist
    Kellerer, Monika
    Klein, Harald H.
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Wiesner, Tobias
    Siegel, Erhard
    DIABETOLOGIE, 2024, : 212 - 260
  • [2] Treatment of type 2 diabetes
    Scheen, AJ
    ACTA CLINICA BELGICA, 2003, 58 (05) : 318 - 324
  • [3] The Treatment of Type 2 Diabetes
    Pfeiffer, Andreas F. H.
    Klein, Harald H.
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2014, 111 (05): : 69 - +
  • [4] Type 2 Diabetes Treatment
    Landgraf, Ruediger
    Kellerer, Monika
    Aberle, Jens
    Fach, Eva-Maria
    Gallwitz, Baptist
    Hamann, Andreas
    Joost, Hans-Georg
    Klein, Harald
    Mueller-Wieland, Dirk
    Nauck, Michael A.
    Reuter, Hans-Martin
    Schreiber, Stephan
    Siegel, Erhard
    DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 : S144 - S165
  • [5] The Treatment of Type 2 Diabetes
    Roth, Christian
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2014, 111 (25): : 432 - 432
  • [6] Current treatment of type 2 diabetes
    Schernthaner, G.
    Schernthaner, G. -H.
    INTERNIST, 2012, 53 (12): : 1399 - +
  • [7] Mitiglinide for type 2 diabetes treatment
    Phillippe, Haley M.
    Wargo, Kurt A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2133 - 2144
  • [8] Type 2 diabetes: pathogenesis and treatment
    Stumvoll, Michael
    Goldstein, Barry J.
    van Haeften, Timon W.
    LANCET, 2008, 371 (9631): : 2153 - 2156
  • [9] Treatment burden in type 2 diabetes
    Kang, Seema
    LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (08): : 615 - 615
  • [10] Treatment of Diabetes mellitus Type 2
    Matthaei, S.
    Bierwirth, R.
    Fritsche, A.
    Gallwitz, B.
    Haering, H. -U.
    Joost, H. -G.
    Kellerer, M.
    Kloos, C.
    Kunt, T.
    Nauck, M.
    Schernthaner, G.
    Siegel, E.
    Thienel, F.
    DIABETOLOGIE UND STOFFWECHSEL, 2011, 6 : S131 - S136